Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancerWilliam N William, Ralph G Zinner, Daniel D Karp, et al.
Molecular Carcinogenesis|July 29, 2003
Prostate-specific antitumor activity by probasin promoter-directed p202 expressionYong Wen, Dipak Giri, Duen-Hwa Yan, et al.
Current Medical Research and Opinion|March 10, 2017
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studiesIsamu Okamoto, Wolfgang H W Schuette, Thomas E Stinchcombe, et al.
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
American Journal of Clinical Oncology|August 19, 2009
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapyWilliam N William, Fadlo R Khuri, Frank V Fossella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Investigational New Drugs|January 23, 2010
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran, Ralph G Zinner, George R Blumenschein, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2008
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.
Pageof 6